Use of recombinant interferon alpha 2 for the treatment of autoimmune uveitis (primary or associated with Behçet disease);Utilización de interferón alfa 2r en el tratamiento de las uveítis autoinmunes (primarias o asociadas a enfermedad de Behçet)

Revista Clinica Espanola

Volumn 196, Issue 5, 1996, Pages 293-298

  Sanchez Roman J ^a,b   Pulido Aguilera, M C ^a   Castillo Palma, M J ^a   Ocana Medina C ^a   Toral Pena A ^a   Lopez Checa F ^a   Wichmann, I ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE   (Spain)

Author keywords

Autoimmune uveitis; Behcet disease; Recombinant interferon (IFN ); Refractory uveitis therapy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; RECOMBINANT ALPHA2A INTERFERON; ALPHA2B INTERFERON;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; FEMALE; HUMAN; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; UVEITIS; ADOLESCENT; AUTOIMMUNE DISEASE; CHILD; MIDDLE AGED; NONPARAMETRIC TEST; PILOT STUDY;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; BEHCET SYNDROME; CHILD; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; UVEITIS;

EID: 0030141109     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Nussenblatt RB Effectiveness of ciclosporin on shigt-threatening endogenous uveitis. En: Schindler R. ed Ciclosporin in autoimmune diseases. Berlin. Springer-Verlag, 1985; 133-136.
2. Nussenblatt RB. Efficacy of ciclosporin therapy for Behçet disease Arthritis Rheum 1985; 28.671-679
3. Benezra D. Evaluation on ciclosporin versus conventional therapy in Behçet's disease. Transplant Proc 1988; 20 (suppl 4):136-143
4. Sanchez Roman J, Varela Aguilar JM Arriaga J, López Checa F. Tratarmiento a largo plazo con ciclosporina en la uveitis posterior En: Symposium sobre Uveitis Endogena. Drugs of Today. 1989 (5 suppl) 39-42.
5. Diaz Llopis M. Menezo JL Cyclosporin for Behcet s disease. A long-term study. Curr Eye Dis 1990: 8 56-60.
6. Pascalis L, Pia G, Aresu G, Frongia T, Barca L. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. Journal of Autoimmunity 1993; 6:467-480.
7. O'Duffy JD, Goldstein NP. Neurologic involvement in seven patients with Behçet's disease Am J Med 1976; 61:170-178.
8. Hoaglin DC, Mosteller F, Tukey JW. Understanding robust and exploratory data analysis. Nueva York John Wiley & Sons, Inc. 1983
9. De Maeyer E. De Maeyer-Guignard. Interferons, En: Thomson AW, ed. The Cytokine Handbook. London: Academic Press, 1991; 215-240.
10. Jacob CO, McDevitt HO Interferon-γ and TNF autoimmune disease models Implications for immunoregulation and genetic susceptibility. En: Talal N, ed. Molecular autoimmunity. London: Academic Press, 1991. 215-240
11. Lemmel EM, Obert HJ, Hofschnerdez PH. Low dose gamma-interferon in treatment of rheumatoid arthritis. Lancet 1988: 1:598.
12. Fierlbeck G, Rassner G. Rekombinantes interferon-gamma bei psoriasis arthropathica, progressiv systemischer sklerodermie und morbus Behcet. Med-Klin 1988. 83:695-699.
13. Nicolas JF, Thivolet J. Interferon alfa therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 1989; 321: 1.550-1.551
14. Sánchez Román J, Castillo Palma MJ, Ocan̄a Medina C, Rodriguez Can̄as T. Tratamiento del pioderma gangrenoso resistente a ciclosporina-A con interferon alfa-2 recombinante. Med Clin (Barc) 1995, 104:517-518.
15. Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994, 53:334-337.
16. Sobrino J, Torres M, Rodriguez E, Titó L. Crioglobulinemia mixta esencial y hepatitis crónica por el virus C Tratamiento con interferón. Med Clin (Barc) 1993; 100:799.
17. Ohno S. Immunological aspects of Behçet's and Voght KoyanagiHarada's disease. Trans Ophthal Soc UK 1981, 101:335-341
18. Jorizzo JL. Behcet's disease. An update based on the 1985 International Conference in London. Arch Dermatol 1986, 122:556-558
19. Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986, 278:335-336.
20. Stadler R, Bratzke B, Baumann I Morbus Behçet und exogenes interferon Erfolgreicher Behandlungsversuch mit rekomniniertem alpha-A-IFN. Hautarzt 1987; 38:97-100.
21. Stadler R, Bratzke B, Orfanos CE. Therapeutischer Einsatz von alpha-interferon bei metastasierendem malignem Melanom, disseminiertem Kaposi-Sarkom un schwerem Morbus Behçet. Hautarzt 1987; 38:453-460.
22. Tata F, Gori E, De Bartolomeis AM. Nouve prospettive terapeutiche in corso di malattia di Behçet il beta-interferone. Recenti Prog Med 1988, 79:135-137.
23. Hamuryudan V, Yurdakul S, Serdaroglu S, Tuzun Y, Rosenkaimer F, Yazici H. Topical alpha-interferon in the treatment of oral ulcers in Behçet syndrome a preliminary report Clin Exp Rheumatol 1990; 8:51-54.
24. Zouboulis CC, Treudler R, Orfanos CE. Morbus Adamantiades-Behçet Therapeutischer Einsatz von systemischem rekombinantem Interferon-a-2a. Hautarzt 1993; 44:440-445.
25. Sánchez Roman J, Pulido C, Castillo MJ, Toral A, López-Checa F, Bravo-Ferrer J Assessment of the treatment with recombinant alpha-interferon in the ophtalmic and mucosal manifestations in patients with Behçet's disease. Rev Esp de Reumatol 1993 (suppl I):209.
26. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serum and cerebrospmal fluid after systemic administration Clinic Pharmacol Therapeutics 1985; 37:85-88.
27. Wills RJ Clinical pharmacokinetics of interferons Clin Pharmacokinet 1990. 5 390-399.
28. Shiozawa S, Kuroki Y, Kim M, Hiroata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992, 35:417-422.
29. Burman P, Karisson A, Öberg K, Alm GV. Autoimmune thyroid disease in interferon treated patients Lancet 1985: 2:100-101.
30. Fentiman IS, Balkwill FR, Thomas BS, Rusell MJ, Todd I. Botazzo GF. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988, 8:1.299-1 303.
31. De Febrer Martínez G. Sola Alberich R, Olivé Plana JM, Masana Marin L. Hipertiroidismo secundario a terapia con interferón Med Clín 1993. 101 157.
32. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy Cancer 1990; 65:2.237-2.242
33. Chazerain P, Meyer O, Kahn MF. Rheumatoid arthritis-like disease after alpha-interferon therapy Ann Intern Med 1992: 116-427
34. Sanchez Román J, Castillo Palma MJ, Garcia Díaz E. Ferrer Ordinez JA. Lupus eritematoso sistémico inducido por tratamiento con interferónalfa recombinante. Med Clin (Barc) 1994. 102 198
35. Ehrenstein MR, McSweeney E, Swana M, Worman CP, Goldstone AH, Isenberg DA. Appearance of anti-DNA antibodies in patients treated with interferon-α Arthritis Rheum 1993, 36 279-280
36. 2b in Behcet s disease. Arthritis Rheum 1993; 36 1.025-1.026.
37. 2b, for refractory ocular Behçet's disease. Lancet 1994; 343:1.428.
38. Kahan BD. Cydosporine. N Engl J Med 1989; 321:1.725-1.737.
39. Ambrus JL, Chadha KC, Anthone S, Anthone R, Sayyid S The alpha-interferon system in patients undergoing renal transplantation and treated with cyclosporine and prednisone. Surg Gynecol Obstet 1993; 176:588-590.
40. Münke MD, Stöckmann F, Ramadori G. Possible association between Behçet's syndrome and chronic hepatitis C virus. N Engl J Med 1995; 332:400-401.
41. Sénchez Roman J, Castillo Palma MJ, Torronteras Santiago R, Varela Aguilar JM, López Checa F, Sánchez García F. Virus herpes tipo I. fenotipo HLA y enfermedad de Behçet. Med Clin (Barc) 1992; 98:366-369.
42. Sanchez Roman J, Rey Romero C, Castillo Palma MJ, Toral Pen̄a A, Calderón E, Leal Noval M, et al. Behçet's disease: HTLV I/II retrovirus markers in a series of 35 patients. Clinical Rheumatology 1994; 13:391.
43. Sánchez Roman J, Castillo Palma MJ, Torronteras Santiago R, Nún̄ez Roldán A. Ausencia de relación entre enfermedad de Behçet e infección por virus de la hepatitis B y C. Med Clín 1996; 106:196.